Generate Biomedicines Inc.
GENB | NASDAQ
$13.20
-$1.26 (-8.71%)
Nov 2, 2026, 3:58 PM ET · Market open
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 |
|---|---|---|---|
PE Ratio | -15.92 | -23.15 | n/a |
PEG Ratio | 4.30 | n/a | n/a |
PS Ratio | 159.80 | 221.82 | n/a |
PB Ratio | 4.74 | 3.11 | n/a |
P/FCF Ratio | -15.12 | -19.04 | n/a |
P/OCF Ratio | -15.64 | -19.93 | n/a |
OCF/S Ratio | -917.71 | -1.11K | n/a |
Debt / Equity Ratio | 0.14 | 0.13 | -0.11 |
Quick Ratio | 8.30 | 9.17 | 2.85 |
Current Ratio | 8.30 | 9.17 | 2.85 |
Asset Turnover | 0.01 | 0.01 | n/a |
Interest Coverage | -462.03 | -352.26 | n/a |
Return on Equity | -14.75% | -11.94% | n/a |
Return on Assets | -11.97% | -9.82% | n/a |
Return on Invested Capital | -13.81% | -11.02% | n/a |
Dividend Yield | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a |
Gross Profit Margin | 100% | 54.69% | n/a |
Net Profit Margin | -1.07K% | -850.58% | n/a |
Pretax Profit Margin | -1.06K% | -853.90% | n/a |
Operating Profit Margin | -1.13K% | -887.49% | n/a |
FCF Margin | -932.48% | -1.17K% | n/a |
EBITDA Margin | -1.01K% | -842.18% | n/a |
Add to Watchlist
Select watchlists to add or remove GENB